NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $10.02 +0.15 (+1.52%) Closing price 04:00 PM EasternExtended Trading$10.04 +0.02 (+0.19%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Iovance Biotherapeutics Stock (NASDAQ:IOVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IOVA alerts:Sign Up Key Stats Today's Range$9.98▼$10.9850-Day Range$3.93▼$10.0252-Week Range$1.76▼$10.98Volume24.18 million shsAverage Volume13.74 million shsMarket Capitalization$4.54 billionP/E RatioN/ADividend YieldN/APrice Target$9.11Consensus RatingHold Company Overview Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. Its platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and returned to the patient to help recognize and attack cancer cells. The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment. Iovance is also evaluating TIL-based therapies and related cell therapy approaches in additional solid tumors, including through clinical development programs designed to address cancers with limited treatment options. Iovance operates an integrated cell therapy manufacturing and development infrastructure intended to support the collection, production and delivery of personalized treatments. The company’s commercial activities are initially centered on the United States, while its research and clinical programs involve collaborations and trial sites in other regions. Iovance was formerly known as Lion Biotechnologies and adopted its current name in 2017.AI Generated. May Contain Errors. Read More Iovance Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreIOVA MarketRank™: Iovance Biotherapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 755th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingIovance Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and 2 sell ratings.Downside RiskIovance Biotherapeutics has a consensus price target of $9.11, representing about 9.1% downside from its current price of $10.02.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Iovance Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($0.49) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -13.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -13.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted21.10% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 5.28.Change versus previous monthShort interest in Iovance Biotherapeutics has recently decreased by 14.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.66 News SentimentIovance Biotherapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 58 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.80% of the stock of Iovance Biotherapeutics is held by insiders.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IOVA Stock News HeadlinesIOVA stock has gained more than 21% in four sessions, and Barclays sees another 52% upside potential - here’s whySeptember 17 at 10:03 AM | msn.comIOVA flags year-end data slate after record Amtagvi quarter, highlights ‘clear line of sight to profitability’September 15 at 10:41 PM | msn.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 17 at 1:00 AM | Banyan Hill Publishing (Ad)Iovance Biotherapeutics (NASDAQ:IOVA) Hits New 1-Year High - Here's WhySeptember 15 at 3:23 AM | americanbankingnews.comFinancial Survey: ADMA Biologics (NASDAQ:ADMA) versus Iovance Biotherapeutics (NASDAQ:IOVA)September 15 at 2:15 AM | americanbankingnews.comIovance Biotherapeutics to Present at Upcoming ConferencesSeptember 4, 2026 | globenewswire.comAustin patients have a new melanoma treatment optionSeptember 1, 2026 | msn.comIovance Biotherapeutics stock is trending Friday: What's going on?August 22, 2026 | msn.comSee More Headlines IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $2.73 at the start of the year. Since then, IOVA shares have increased by 267.0% and is now trading at $10.02. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company's quarterly revenue was up 65.7% on a year-over-year basis. Read the conference call transcript. Who are Iovance Biotherapeutics' major shareholders? Top institutional investors of Iovance Biotherapeutics include BlackRock Inc. (8.28%), Palo Alto Investors LP (1.17%), Bank of America Corp DE (1.10%) and Rice Hall James & Associates LLC (0.34%). Insiders that own company stock include Merrill A Mcpeak, Raj K Puri and Ryan D Maynard. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2026Today9/17/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IOVA's financial health is in the Green zone, according to TradeSmith. IOVA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IOVA CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees975Year Founded2013Price Target and Rating Average Price Target for Iovance Biotherapeutics$9.11 High Price Target$15.00 Low Price Target$2.00 Potential Upside/Downside-9.1%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$390.98 million Net Margins-89.11% Pretax Margin-90.42% Return on Equity-40.51% Return on Assets-31.65% Debt Debt-to-Equity RatioN/A Current Ratio4.34 Quick Ratio3.82 Sales & Book Value Annual Sales$324.97 million Price / Sales13.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book5.69Miscellaneous Outstanding Shares452,971,000Free Float417,639,000Market Cap$4.54 billion OptionableOptionable Beta0.83 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:IOVA) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
